Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Trial Details

NCT ID
NCT05592015
Phase
PHASE2
Sponsor
Jonathan Brammer
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Ruxolitinib
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Age 18 or older and able to swallow pills
  • Diagnosis of T-LGLL defined as: LGL cell population meeting diagnostic criteria (defined as CD3+CD8+ cell population \>650/mm3 or CD3+CD8+CD57+ pop…
  • Untreated T-LGLL or failed at least one line of frontline therapy;
  • Patients must be off treatment for at least 14 days or 5 half-lives, whichever is longer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →